Tags

Type your tag names separated by a space and hit enter

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Exp Neurol. 2000 May; 163(1):239-43.EN

Abstract

In the setting of nigrostriatal dopamine depletion, glutamatergic pathways to the striatum and basal ganglia output nuclei become overactive. Systemically administered glutamate receptor antagonists may have direct antiparkinsonian actions in rodents, but there is little evidence for this in primates. Glutamate antagonists may also potentiate conventional dopaminergic therapies; however, there is concern that broad spectrum, nonselective antagonists may have unwanted side-effects. Because subunit-selective antagonists may avoid these liabilities, we have examined the antiparkinsonian effects of a selective antagonist of the NR2B subunit of the NMDA receptor. In rats, CP-101,606 decreased haloperidol-induced catalepsy with an ED(50) of about 0.5 mg/kg. In MPTP-treated monkeys, CP-101,606 (1 mg/kg) reduced parkinsonian motor symptoms by 20%. At a dose of 0.05 mg/kg, CP-101,606 markedly potentiated the effect of a submaximal dose of levodopa, reducing motor symptoms by about 50% compared to vehicle and by about 30% compared to levodopa alone. No side-effects were apparent at any dose of CP-101,606. We conclude that CP-101,606 has direct antiparkinsonian actions in both rodents and monkeys and it synergistically potentiates levodopa in MPTP-treated monkeys. Clinical evaluation of selective NR2B antagonists may be warranted in Parkinson's disease.

Authors+Show Affiliations

Department of Neuroscience, Finch University of Health Sciences, North Chicago, Illinois 60064, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10785463

Citation

Steece-Collier, K, et al. "Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-containing N-methyl-d-aspartate Receptors." Experimental Neurology, vol. 163, no. 1, 2000, pp. 239-43.
Steece-Collier K, Chambers LK, Jaw-Tsai SS, et al. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163(1):239-43.
Steece-Collier, K., Chambers, L. K., Jaw-Tsai, S. S., Menniti, F. S., & Greenamyre, J. T. (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Experimental Neurology, 163(1), 239-43.
Steece-Collier K, et al. Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-containing N-methyl-d-aspartate Receptors. Exp Neurol. 2000;163(1):239-43. PubMed PMID: 10785463.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. AU - Steece-Collier,K, AU - Chambers,L K, AU - Jaw-Tsai,S S, AU - Menniti,F S, AU - Greenamyre,J T, PY - 2000/4/29/pubmed PY - 2000/6/17/medline PY - 2000/4/29/entrez SP - 239 EP - 43 JF - Experimental neurology JO - Exp Neurol VL - 163 IS - 1 N2 - In the setting of nigrostriatal dopamine depletion, glutamatergic pathways to the striatum and basal ganglia output nuclei become overactive. Systemically administered glutamate receptor antagonists may have direct antiparkinsonian actions in rodents, but there is little evidence for this in primates. Glutamate antagonists may also potentiate conventional dopaminergic therapies; however, there is concern that broad spectrum, nonselective antagonists may have unwanted side-effects. Because subunit-selective antagonists may avoid these liabilities, we have examined the antiparkinsonian effects of a selective antagonist of the NR2B subunit of the NMDA receptor. In rats, CP-101,606 decreased haloperidol-induced catalepsy with an ED(50) of about 0.5 mg/kg. In MPTP-treated monkeys, CP-101,606 (1 mg/kg) reduced parkinsonian motor symptoms by 20%. At a dose of 0.05 mg/kg, CP-101,606 markedly potentiated the effect of a submaximal dose of levodopa, reducing motor symptoms by about 50% compared to vehicle and by about 30% compared to levodopa alone. No side-effects were apparent at any dose of CP-101,606. We conclude that CP-101,606 has direct antiparkinsonian actions in both rodents and monkeys and it synergistically potentiates levodopa in MPTP-treated monkeys. Clinical evaluation of selective NR2B antagonists may be warranted in Parkinson's disease. SN - 0014-4886 UR - https://www.unboundmedicine.com/medline/citation/10785463/Antiparkinsonian_actions_of_CP_101606_an_antagonist_of_NR2B_subunit_containing_N_methyl_d_aspartate_receptors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-4886(00)97374-6 DB - PRIME DP - Unbound Medicine ER -